Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells |
Trade Name | |
Synonyms | |
Drug Descriptions |
Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells are engineered T cells expressing chimeric antigen receptor consisted of CD19 linked to CD8, CD28, and TCR/CD3-zeta, a co-expressing membrane-bound IL-15 and IL-15 receptor fusion protein (mbIL15), and a truncated EGFR (HER1t), which may lead to cytotoxic immune response against CD19-expressing tumor cells (NCI Drug Dictionary). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | C150906 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells | CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells | 0 | 0 |
CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells + Cyclophosphamide + Fludarabine | CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells Cyclophosphamide Fludarabine | 0 | 1 |